- Home
- CTNM vs ACV Comparison
CTNM vs ACV Comparison
Compare CTNM & ACV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- ACV
- Stock Information
- Founded
- CTNM 2009
- ACV 2015
- Country
- CTNM United States
- ACV United States
- Employees
- CTNM N/A
- ACV N/A
- Industry
- CTNM
- ACV Finance/Investors Services
- Sector
- CTNM
- ACV Finance
- Exchange
- CTNM Nasdaq
- ACV Nasdaq
- Market Cap
- CTNM 199.3M
- ACV 233.8M
- IPO Year
- CTNM 2024
- ACV N/A
- Fundamental
- Price
- CTNM $7.59
- ACV $22.00
- Analyst Decision
- CTNM Strong Buy
- ACV
- Analyst Count
- CTNM 4
- ACV 0
- Target Price
- CTNM $29.25
- ACV N/A
- AVG Volume (30 Days)
- CTNM 56.2K
- ACV 38.8K
- Earning Date
- CTNM 03-04-2025
- ACV 01-01-0001
- Dividend Yield
- CTNM N/A
- ACV 9.20%
- EPS Growth
- CTNM N/A
- ACV N/A
- EPS
- CTNM N/A
- ACV N/A
- Revenue
- CTNM N/A
- ACV N/A
- Revenue This Year
- CTNM N/A
- ACV N/A
- Revenue Next Year
- CTNM N/A
- ACV N/A
- P/E Ratio
- CTNM N/A
- ACV N/A
- Revenue Growth
- CTNM N/A
- ACV N/A
- 52 Week Low
- CTNM $7.04
- ACV $16.82
- 52 Week High
- CTNM $22.00
- ACV $23.74
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- ACV 35.73
- Support Level
- CTNM N/A
- ACV $22.61
- Resistance Level
- CTNM N/A
- ACV $22.85
- Average True Range (ATR)
- CTNM 0.00
- ACV 0.34
- MACD
- CTNM 0.00
- ACV -0.10
- Stochastic Oscillator
- CTNM 0.00
- ACV 4.24
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It seeks to achieve its investment objective by investing in a combination of convertible securities, debt and other income-producing instruments and common stocks and other equity securities.